湖南方盛制药股份有限公司关于公司参与投资设立的并购基金对外出售投资项目部分股份的提示性公告

Core Viewpoint - The announcement details the investment and share transfer activities of Hunan Fangsheng Pharmaceutical Co., Ltd. and its affiliated investment partnership, focusing on the sale of shares in Hunan Kexin Health Industry Group Co., Ltd. and the implications for the company's capital recovery [2][10]. Group 1: Investment and Share Transfer Details - Hunan Kexin has decided to transfer 51% of its shares in Changsha Kexin Tumor Hospital Co., Ltd. to Yinkang Life Science Co., Ltd. for RMB 357 million, with subsequent transfers of 29% and 20% shares planned based on performance commitments [2][6]. - The company has invested RMB 100 million in the affiliated partnership, initially holding a 16.67% stake, which increased to 21.25% after changes in partner contributions [3][4]. - As of the announcement date, the company has recovered RMB 1.5 million of its investment, with RMB 98.5 million still outstanding [3][8]. Group 2: Financial Implications and Recovery Plans - The expected recovery from the share transfer is estimated at RMB 154.68 million, with the first phase of recovery projected to be RMB 87.61 million [6][8]. - The partnership has a commitment from a subordinate partner to cover any investment losses if the recovery does not meet the required amounts [8][10]. - The company plans to negotiate with partners to ensure the recovery of its outstanding investment before the partnership's expiration in January 2026 [9][10].